A 60-year-old man was treated with rifampicin, isoniazid, ethambutol and pyrazinamide for pulmonary tuberculosis. Acute renal failure developed 1 month after re-administration of rifampicin following 1 month’s interruption of treatment. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis. This is, to our knowledge, the fourth case of rapidly progressive crescentic glomerulonephritis associated with rifampicin treatment, which responded to methylprednisolone pulse therapy followed by oral steroid therapy.

Keywords:
Rapidly progressive glomeruolonephritis, Rifampicin, Acute renal failure
1.
Gabow PA, Lacher JW, Neff TA: Tubulointerstitial and glomerular nephritis associated with rifampicin. JAMA 1976;23:2517–2518.
2.
Hirsch DJ, Bia FJ, Kashgarian M, Bia MJ: Rapidly progressive glomerulonephritis during antituberculous therapy. Am J Nephrol 1983;3:7–10.
3.
Murray AN, Cassidy MJD, Tempecamp C: Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis. Nephron 1987;46:373–376.
4.
Ogata H, Kubo M, Tamaki K, Hirakata H, Okuda S, Fujishima M: Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. Nephron 1998;78:319–322.
5.
De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lamerire NH: Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 1998;31:108–115.
6.
Levy JB, Winearls CG: Rapidly progressive glomerulonephritis: What should be first-line therapy? Nephron 1994;67:402–407.
© 2002 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.